<DOC>
	<DOCNO>NCT01781572</DOCNO>
	<brief_summary>In phase Ib , primary purpose establish maximum tolerate dose ( MTD ) ( ) /recommended phase dose ( RP2D ) schedule LEE011 MEK162 orally administer combination . Once MTD ( ) /RP2D determine tested schedule , additional patient enrol phase II portion study RP2D chosen schedule order assess anti-tumor activity combination addition continue evaluation safety .</brief_summary>
	<brief_title>A Phase Ib/II Study LEE011 Combination With MEK162 Patients With NRAS Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients enrol phase Ib may enrol evaluable disease . Patients enrol phase II expansion must least one measurable lesion define RECIST 1.1 criterion solid tumor . Patients must adequate organ function , define follow parameter 1 . Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L . 2 . Hemoglobin ( Hgb ) ≥ 9 g/dL . 3 . Platelets ≥ 75 x 109/L without transfusion within 21 day 1st treatment . 4 . PT/INR aPTT ≤ 1.5 ULN . 5 . Serum creatinine ≤1.5 ULN . 6 . Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . 7 . AST ALT ≤ 3 x ULN , except patient tumor involvement liver must AST ALT ≤ 5 x ULN . Presence brain metastasis detect MRI CT i.v . contrast brain screening . Uncontrolled arterial hypertension despite medical treatment Impaired cardiac function clinically significant cardiac disease , include follow : 1 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % determined multiple gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) . 2 . Congenital long QT syndrome family history unexpected sudden cardiac death . 3 . QTcF correct Frederica 's Bazett 's formula QTcB &gt; 450 m male &gt; 470 m female screen ECG . 4 . Angina pectoris ≤ 3 month prior start study drug 5 . Acute myocardial infarction ≤ 3 month prior start study drug 6 . Clinically significant rest bradycardia 7 . History presence ventricular tachyarrhythmia 8 . Unstable atrial fibrillation ( ventricular response &gt; 100 bpm ) 9 . Complete leave bundle branch block 10 . Right bundle branch block leave anterior hemi block ( bifascicular block ) 11 . Obligate use cardiac pacemaker implantable cardioverter defibrillator 12 . Any clinically significant heart disease Patients currently receive treatment agent know cause QTc prolongation human . Patients neuromuscular disorder associate elevated CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) elevate baseline CK level ( ≥ Grade 2 ) Patients currently receive treatment agent metabolize predominantly CYP3A4 narrow therapeutic window . Patients concurrent severe and/or uncontrolled concurrent medical condition could compromise participation study ( i.e . uncontrolled diabetes mellitus , clinically significant pulmonary disease , clinically significant neurological disorder , active uncontrolled infection ) . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) . Other protocol relate inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>